AVACLYR Drug Patent Profile
When do Avaclyr patents expire, and when can generic versions of Avaclyr launch?
Avaclyr is a drug marketed by Fera Pharms Llc and is included in one NDA.
The generic ingredient in AVACLYR is acyclovir. There is one drug master file entry for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the acyclovir profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Avaclyr
A generic version of AVACLYR was approved as acyclovir by TEVA on April 22nd, 1997.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AVACLYR?
- What are the global sales for AVACLYR?
- What is Average Wholesale Price for AVACLYR?
Summary for AVACLYR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 184 |
| What excipients (inactive ingredients) are in AVACLYR? | AVACLYR excipients list |
| DailyMed Link: | AVACLYR at DailyMed |
US Patents and Regulatory Information for AVACLYR
AVACLYR is protected by zero US patents and one FDA Regulatory Exclusivity.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fera Pharms Llc | AVACLYR | acyclovir | OINTMENT;OPHTHALMIC | 202408-001 | Mar 29, 2019 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
